{"filings":[{"id":99754,"accession_number":"0000917520-26-000044","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Integra LifeSciences shareholders approve 3.55M share increase to equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 3 to increase shares available under the plan by 3,550,000 to 24,250,000 total shares.","All 7 director nominees were elected; Barbara B. Hill received the most votes against (7,042,475).","Ratification of PricewaterhouseCoopers as 2026 auditor passed with 72,313,820 votes for.","Advisory say-on-pay approved with 68,472,769 votes for.","Equity plan amendment received 68,005,433 votes for and 1,269,231 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99753,"accession_number":"0000917520-26-000034","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.","Mojdeh Poul departed as President and CEO and from the Board effective April 30, 2026; she receives $566,526 lump sum.","Essig receives $1,075,000 base salary, 125% target bonus, and initial equity awards totaling $8 million in RSUs and options.","Michael McBreen appointed Chief Commercial Officer with base salary $660,000 and $1,000,000 one-time equity award.","Essig previously served as Integra's CEO from 1997 to 2012 and as Executive Chairman from February 2024 to June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99752,"accession_number":"0000917520-26-000033","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.","Adjusted EPS $0.54 vs $0.41; adjusted gross margin 64.1% vs 62.2%. Adjusted EBITDA $76.2M (19.4% rev).","Specialty Surgery rev $283.1M (+0.9% rep, -0.6% organic); Tissue Reconstruction $108.8M (+6.7% rep, +6.4% organic).","Reaffirms FY rev guidance $1.662B-$1.702B; raises adj. EPS guidance to $2.40-$2.50 from $2.30-$2.40.","Braintree facility on track to begin SurgiMend production by end of June for Q4 launch; PriMatrix/Durepair returning."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":391918000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99751,"accession_number":"0000917520-26-000019","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Integra LifeSciences amends $150M A/R facility, extends termination to April 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Scheduled termination date of $150M accounts receivable securitization facility extended to April 10, 2029.","Amends representations, covenants, and concentration limits under the Receivables Financing Agreement.","Also amends Purchase and Sale Agreement with similar covenant changes; PNC Bank remains administrative agent.","The Bank of Nova Scotia remains a committed lender and group agent under the facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115934,"accession_number":"0000917520-26-000008","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q4 rev -1.7% organic; FY GAAP loss $6.74/sh on $511M goodwill impairment; 2026 adj EPS guidance $2.30-$2.40","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.","FY 2025 revenues $1,635.2M (+1.5% reported, -0.7% organic); GAAP net loss $516.5M ($6.74/sh) includes $511M goodwill impairment.","Codman Specialty Surgical segment rev $323.3M (+2.7% reported); Tissue Technologies rev $111.6M (-12.8% reported) driven by MediHoney remediation and Integra Skin comp.","2026 guidance: revenues $1,662-$1,702M (0.8%-3.3% organic growth); adj EPS $2.30-$2.40; Q1 2026 rev $375-$390M.","Transformation plan simplifies operating model targeting $25-$30M savings in 2026; net debt $1.6B, leverage 4.5x, liquidity $516M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":1635245000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132349,"accession_number":"0000917520-25-000100","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra adopts CIC severance program; CFO gets 2x multiple","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Program effective Jan 1, 2026; covers Lea Knight (CFO), Robert Davis, Michael McBreen, Harvinder Singh.","Qualifying termination within 2 years after a change in control triggers severance: 1.5x (2x for CFO) of base salary plus target bonus.","Benefits include lump-sum cash, pro-rated bonus, 18 months of COBRA subsidies, and 12 months of outplacement.","Program automatically extends to 2 years post-change in control; subject to release and 'best pay cap' excision tax limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132348,"accession_number":"0000917520-25-000094","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.","GAAP net loss $(5.4)M ($(0.07)/diluted share); adjusted EPS $0.54 vs $0.41 YoY.","Codman Specialty Surgical revenues $292.6M (+8.1% reported); Tissue Technologies $109.5M (-0.5% reported).","Full-year 2025 revenue guidance cut to $1.620B-$1.640B (organic growth -1.6% to -0.4%); adj EPS $2.19-$2.24.","Relaunched PriMatrix and Durepair ahead of schedule; Braintree facility on track for production in June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":1200320000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148927,"accession_number":"0000917520-25-000069","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.","GAAP net loss $484.1M includes $511M goodwill impairment; adjusted EBITDA $71.2M (17.1% margin) vs $83.8M (20.0%) prior year.","Full-year 2025 revenue guidance narrowed to $1.655B–$1.680B; adj EPS reaffirmed at $2.19–$2.29.","Net debt $1.59B; total leverage ratio 4.5x; liquidity ~$1.14B including $254M cash and short-term investments.","Completed all manufacturing site baseline assessments under Compliance Master Plan; no new shipping holds in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":798258000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167848,"accession_number":"0000917520-25-000060","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.","Ratio steps down to 4.75:1 (Sep 2026), 4.50:1 (Dec 2026), and 4.00:1 (Mar 2027 onward).","No increase in total indebtedness; temporary restrictions on investments, liens, and restricted payments during Covenant Relief Period.","Amendment effective June 6, 2025, to Seventh Amended and Restated Credit Agreement dated March 24, 2023.","Company temporarily prohibited from using leverage 'step-up' for permitted acquisitions during Covenant Relief Period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167847,"accession_number":"0000917520-25-000052","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Integra LifeSciences shareholders approve 2.2M share increase in equity plan; chairman transitions to non-executive role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved Amendment No. 2 to increase shares under equity plan by 2.2M, to 20.7M total.","All nine director nominees elected at May 9 annual meeting; PwC ratified as auditor; say-on-pay approved.","Board approved transition of Dr. Essig from Executive Chairman to non-executive Chairman effective July 1, 2025; no disagreement.","Plan amendment eliminates provision allowing shares withheld for taxes to be returned to the plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167846,"accession_number":"0000917520-25-000038","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).","Adjusted EPS $0.41 vs $0.55 prior year; adjusted gross margin 62.2% vs 64.4%.","Codman Specialty Surgical organic revenue -1.1%; Tissue Technologies organic -9.1%.","Full-year 2025 revenue reaffirmed $1.65B-$1.715B; adj EPS guidance reduced to $2.19-$2.29 (incl $(0.22) tariff impact).","Q2 2025 guidance: revenue $390M-$400M, adj EPS $0.40-$0.45; operating cash flow negative $(11.3)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":382653000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185095,"accession_number":"0000917520-25-000014","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q4 adj EPS $0.97 (+9% YoY); FY24 GAAP EPS ($0.09); 2025 adj EPS guidance $2.41-$2.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.","FY2024: rev $1,610.5M (+4.5% rep, -1.3% org); GAAP EPS ($0.09) vs $0.84; adj EPS $2.56 vs $3.10.","FY2025 guidance: rev $1,650M-$1,715M (+2.4-6.5% rep, +1.0-5.0% org); adj EPS $2.41-$2.51 (below 2024 adj EPS $2.56).","Q1 2025 guidance: rev $375M-$385M (+1.6-4.4% rep); org rev -6.2% to -3.5% due to ship holds & Integra Skin delays.","Net debt $1.5B; leverage ratio 4.0x; FY2024 cash from ops $129.4M, capex $104.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1610527000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185094,"accession_number":"0000917520-25-000004","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Integra LifeSciences receives FDA warning letter for quality system violations at three facilities","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter dated Dec 19, 2024, for quality system issues at Mansfield, MA; Plainsboro, NJ; Princeton, NJ facilities.","Products cited: cranial perforators, cottonoid patties, strips, collagen-based products; shipping holds and voluntary recall of patties/strips previously initiated.","Warning letter does not restrict manufacturing/shipment or require recall; premarket approval for related Class III devices blocked until violations resolved.","Company reaffirms Q4 revenue guidance of $441M-$451M; expects no material impact from warning letter.","Company is executing a compliance master plan and preparing a written response to the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201708,"accession_number":"0000917520-24-000121","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences adopts Change in Control Severance Program effective Jan 1, 2025, renewing expiring program","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Program covers named executives including CFO Lea Knight, with severance multiple of 2x (1.5x for others) base salary plus target bonus.","Qualifying termination (without cause or for good reason) within 2 years after a change in control triggers lump-sum severance, prorated bonus, COBRA for 18 months, and outplacement.","Program term runs through Dec 31, 2025, with automatic extension upon a change in control until 2-year anniversary.","Benefits subject to general release of claims and potential 'best pay cap' reduction for excise tax under Section 4999."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201707,"accession_number":"0000917520-24-000106","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.","Neurosurgery organic sales -16% on shipping holds; Instruments +8.7%; Tissue Tech -3.7% organic, ex-Boston -9.4%.","FY2024 revenue guidance lowered to $1.609-1.619B (organic -1.7% to -1.0%); adjusted EPS guided $2.41-$2.49.","Mojdeh Poul named next president and CEO, effective Jan 6, 2025, succeeding retiring Jan De Witte.","Shipping holds releasing in line with expectations; Integra Skin production on pace for Q4 historical run rates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1167881000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201706,"accession_number":"0000917520-24-000105","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Integra LifeSciences names Mojdeh Poul as President & CEO effective Jan 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mojdeh Poul appointed President & CEO, effective January 6, 2025, succeeding Jan De Witte.","Poul previously EVP & Group President of 3M's $8.5B global healthcare business.","Poul to receive base salary of $1.05M, target bonus 125%, and initial equity awards totaling $6.75M.","Jan De Witte's resignation is part of a previously announced succession plan; no disagreement.","Stuart Essig to remain Executive Chairman temporarily before returning to non-executive role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217689,"accession_number":"0000917520-24-000092","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.","Revenue $418.2M, up 9.7% reported, 2.3% organic; organic ex-Boston +0.3%. Adjusted gross margin 65.2% (down from 67.6%).","Codman Specialty Surgical rev $301.8M (+11.3% reported, +0.9% organic). Tissue Technologies $116.4M (+5.6% reported, +5.7% organic; -1% ex-Boston).","FY2024 guidance cut: revenue $1.609-1.629B, adjusted EPS $2.41-2.57. Cites temporary shipping holds and investments in quality/GMP compliance.","Received PMA approvable for SurgiMend pending GMP certification; Braintree facility operational readiness expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":787047000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237591,"accession_number":"0000917520-24-000074","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Integra LifeSciences enters $50M accelerated share repurchase with Morgan Stanley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed ASR agreement on May 16, 2024 with Morgan Stanley & Co. LLC.","Repurchase covers $50M of common stock (par value $0.01).","Transaction expected to be completed in the third quarter of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237590,"accession_number":"0000917520-24-000066","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Integra LifeSciences plans $50M share repurchase; stockholders approve equity plan amendment adding 1.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorizes $50M share repurchase program; repurchases expected to begin Q2 2024 subject to market conditions.","Stockholders approved Plan Amendment: share reserve increased by 1.9M shares; tax withholding share recycling eliminated.","All eight director nominees elected with strong support (>93% of votes cast); PricewaterhouseCoopers ratified as auditor for FY2024.","Stockholders approved charter amendment to limit liability of certain officers as permitted by Delaware law (62.6M for, 9.3M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237589,"accession_number":"0000917520-24-000059","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.","Adjusted EPS $0.55 vs $0.74 prior year; adjusted EBITDA $71.8M (19.5% rev) vs $92.3M (24.2%).","Acclarent acquisition closed April 1; FY2024 revenue guidance raised to $1.672-1.687B, adj. EPS guidance $3.01-3.11.","Tissue Technologies revenue fell 15.3% driven by Boston recall; removing SurgiMend/PriMatrix relaunch from guidance due to audit findings.","Codman Specialty Surgical grew 3.3% reported (4.4% organic); Neurosurgery up 6.3% organically, Instruments down 2.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":368872000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255129,"accession_number":"0000917520-24-000018","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Integra LifeSciences CEO Jan De Witte to retire by end of 2024; Stuart Essig named Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jan De Witte to retire as President and CEO by end of 2024 after successor appointed; will remain until transition.","Stuart Essig, current Chairman, appointed Executive Chairman effective immediately to lead transition.","Board engaged Heidrick & Struggles to search for new CEO candidate; expects to appoint successor by end of 2024.","De Witte to serve as Senior Advisor from transition date through March 2026 under consulting agreement with base salary and bonus eligibility.","De Witte's retirement is for personal reasons, not due to disagreement with company operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255128,"accession_number":"0000917520-24-000017","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q4 GAAP EPS $0.25 vs $0.63; guides FY2024 revenue up 4-5% organic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenues $397.0M, down 0.2% reported; organic revenue ex-Boston up 3.6%.","GAAP EPS $0.25, adjusted EPS $0.89 vs $0.94 prior year.","Full-year 2023 adjusted EPS $3.10 vs $3.36; Boston relaunch on track for mid-to-late Q2 2024.","Signed definitive agreement to acquire Acclarent ENT business expected to close by Q2 2024.","FY2024 guidance: revenue $1,603M-$1,618M (organic +4-5%), adjusted EPS $3.15-$3.25."],"consensus_eps_estimate":null,"consensus_eps_actual":0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":1541573000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255127,"accession_number":"0000917520-24-000011","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K/A","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Integra LifeSciences adds director Jeffrey Graves to Compensation Committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jeffrey Alan Graves appointed to Compensation Committee effective February 21, 2024.","Graves was originally appointed to the Board on December 12, 2023.","Committee assignment fills the remaining governance detail from the initial appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272591,"accession_number":"0000917520-23-000082","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Integra LifeSciences extends A/R securitization facility maturity to Dec 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 5 extends the $150M A/R securitization facility maturity to December 15, 2026.","Facility originally entered Dec 2018; parties include Integra Receivables, ILS Sales, PNC Bank, and Bank of Nova Scotia.","Company's limited performance guaranty continues in accordance with its terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272590,"accession_number":"0000917520-23-000079","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences appoints Jeff Graves to board; adopts exec severance program","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Alan Graves, CEO of 3D Systems, appointed to board effective Dec 12, 2023, filling an existing vacancy.","Graves is independent; will receive pro-rated annual retainer and director equity grants under standard policy.","Change in control severance program adopted effective Jan 1, 2024, covering CFO Lea Knight and other named executives.","Program provides lump sum of 1.5x (2x for CFO) base salary plus target bonus, COBRA, and outplacement upon qualifying termination.","Program expires Dec 31, 2024, but automatically extends for two years upon a change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272589,"accession_number":"0000917520-23-000077","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Integra LifeSciences to acquire Acclarent from Ethicon for $275M cash plus $5M milestone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $275M in cash at closing, plus $5M regulatory milestone; acquisition of all outstanding shares of Acclarent.","Acclarent generated ~$110M revenue in 2022 with gross margins in line with Integra's company average.","Deal expected to close by Q2 2024, subject to HSR clearance, IIA approval, and other customary conditions.","Acquisition is accretive to Integra's long-range plan and adds ~$1B to CSS total addressable market.","Acclarent's ENT portfolio (balloon dilation, navigation systems) is adjacent to Integra's neurosurgery business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272588,"accession_number":"0000917520-23-000069","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q3 revenues down 0.7%, GAAP EPS $0.24; adjusts FY23 guidance lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $382.4M, reported -0.7% YoY; organic ex-Boston +7.1%.","GAAP EPS $0.24 vs $0.60; adjusted EPS $0.76 vs $0.86.","Codman Specialty Surgical +7.4% organic; Tissue Technologies -15.1% organic due to Boston recall returns.","FY23 revenue guidance cut to $1.541-1.547B; adjusted EPS $3.10-3.14.","Boston facility restart on track for Q4'23; commercial distribution expected mid-to-late Q2'24."],"consensus_eps_estimate":null,"consensus_eps_actual":0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":1144534000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289428,"accession_number":"0000917520-23-000065","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Integra LifeSciences enters $125M accelerated share repurchase with Wells Fargo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Wells Fargo to repurchase $125M of common stock via accelerated share repurchase.","Repurchase expected to complete in the fourth quarter of 2023.","Action reduces outstanding shares, potentially boosting EPS for remaining shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289427,"accession_number":"0000917520-23-000060","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Integra Q2 adj EPS $0.71, revenue $381M (-4.2%); FDA warning on Boston facility; guides down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP diluted EPS $0.05 vs $0.54; adjusted EPS $0.71 vs $0.82; revenue $381.3M declined 4.2% reported, 2.7% organic.","Codman Specialty Surgical organic growth 6.3%; Tissue Technologies organic decline 19.7% due to Boston recall impact.","FDA warning letter (July 17, 2023) for Boston facility quality systems; does not restrict shipping but requires annual third-party audit for three years.","Planning $125M share repurchase in Q3 under new $225M board authorization; replaced prior program.","Updated FY2023 guidance: revenue $1.548-1.560B, adj EPS $3.10-3.18; Boston restart late Q4'23, commercial distribution mid-Q2'24."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":762113000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310245,"accession_number":"0000917520-23-000054","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Integra LifeSciences appoints Lea Daniels Knight as EVP and CFO effective June 28","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Knight brings over 30 years of experience, most recently as EVP Business Finance at Booz Allen Hamilton, and 18 years at Johnson & Johnson.","Compensation includes $600K base salary, 90% target bonus, $1M RSU grant, $350K cash sign-on, and $1.65M 2024 LTI target.","Jeff Mosebrook ceases as principal financial officer but remains SVP Finance and principal accounting officer.","Appointment effective June 28, 2023; Knight succeeds interim CFO role held since February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310244,"accession_number":"0000917520-23-000035","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["2.06","7.01"],"status":"ready","headline":"Integra LifeSciences initiates global product recall due to endotoxin issues, cuts guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary recall of SurgiMend, PriMatrix, Revize, TissueMend from Boston facility (March 2018 – May 2023).","Expects $22M inventory impairment charge in Q2 ending June 30, 2023; no cash impact.","Q2 2023 guidance revised: revenue $372M-$376M, adjusted EPS $0.55-$0.59.","If stoppage continues through 2023, full-year revenue impact ~$60M, EPS ~$0.35.","Boston facility products represent ~5% of consolidated revenues; manufacturing halt extended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310243,"accession_number":"0000917520-23-000032","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Integra LifeSciences stockholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Barbara B. Hill received highest votes against (6.6M).","PricewaterhouseCoopers LLP ratified as 2023 auditor with 78.4M for, 0.7M against.","Advisory say-on-pay approved with 73.6M for (95.8% of votes cast).","Stockholders voted 75.9M for annual say-on-pay frequency; Board adopts annual vote.","Meeting held May 12, 2023; results filed by May 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310242,"accession_number":"0000917520-23-000026","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q1 revenue $380.8M, organic growth 4.6%; adj EPS $0.74 flat YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $380.8M, +1.1% reported, +4.6% organic vs Q1 2022.","GAAP EPS $0.29 vs $0.39 prior year; adjusted EPS $0.74 flat.","Codman Specialty Surgical $248.1M (+3.5% organic); Tissue Technologies $132.7M (+6.8% organic).","Full-year 2023 guidance reaffirmed: revenue $1,602-1,620M, adj EPS $3.43-3.51.","Initiated $150M accelerated share repurchase; amended credit facility extended to 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":380846000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328900,"accession_number":"0000917520-23-000017","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Integra LifeSciences enters $2.075B credit agreement, extends maturity to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit facility: $1.3B revolver and $775M term loan, total $2.075B.","Maturity extended from Feb 2025 to Mar 24, 2028, with springing conditions.","Interest at Term SOFR + 1.00%-1.75% or base rate; commitment fee 0.15%-0.30%.","Proceeds used for general corporate purposes, replacing prior 2020 credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328899,"accession_number":"0000917520-23-000012","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q4 adj EPS $0.94, rev $398M; FY2023 guidance rev $1.60-1.62B, adj EPS $3.43-3.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenues $398.0M (-1.8% reported, +2.9% organic); GAAP EPS $0.63, adj EPS $0.94.","Full-year 2022 revenues $1,557.7M (+1.0% reported, +4.2% organic); GAAP EPS $2.16, adj EPS $3.36.","FY2023 guidance: revenues $1,602M-$1,620M (organic growth 4.0%-5.2%), adj EPS $3.43-$3.51.","Entered $150M accelerated share repurchase agreement with Goldman Sachs, expected to complete in H1 2023.","Codman Specialty Surgical organic growth 1.8%; Tissue Technologies organic growth 5.0% in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1557666000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328898,"accession_number":"0001193125-23-016584","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Integra LifeSciences enters $150M accelerated share repurchase agreement with Goldman Sachs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchase of $150M of common stock via accelerated share repurchase with Goldman Sachs & Co. LLC.","Transactions expected to be completed in the first half of 2023.","Shares have par value $0.01 per share; program reduces outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328897,"accession_number":"0000917520-23-000008","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Integra LifeSciences raises adj EPS guidance for Q4 and FY2022 above prior expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 adjusted EPS expected $0.92-$0.96 vs $0.84 in Q4 2021; above Oct guidance high end.","FY 2022 adjusted EPS expected $3.34-$3.38 vs $3.18 in FY 2021; above Oct guidance high end.","Preliminary, unaudited results; full Q4 & FY 2022 earnings due Feb 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1557666000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328896,"accession_number":"0000917520-23-000007","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Integra LifeSciences CFO Carrie Anderson resigns effective Feb 2, 2023; interim finance leaders appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Carrie Anderson resigns effective February 2, 2023 to pursue another professional opportunity.","Company will conduct a search for a new CFO; Mathieu Aussermeier and Jeffrey Mosebrook assume interim duties.","Jeffrey Mosebrook will serve as principal financial officer and principal accounting officer during the interim.","Aussermeier covers treasury, FP&A, IR; Mosebrook oversees accounting, tax, audit, and global business services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328895,"accession_number":"0000917520-23-000003","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Integra pre-announces Q4 rev ~$397-398M, adj EPS above guidance; FY rev ~$1,557-1,558M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue expected $397M-$398M, down ~2% reported, up ~3% organic vs Q4 2021.","Adjusted EPS expected above high end of October guidance range.","FY2022 revenue expected $1,557M-$1,558M, up ~1% reported, +4% organic.","Full-year adjusted EPS above high end of October guidance and above midpoint of original Feb guidance.","Company presenting at JP Morgan Healthcare Conference on Jan 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1557666000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346555,"accession_number":"0000917520-22-000061","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adopts change-in-control severance (1.5x-2x) for three executives; effective Jan 1, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Covers CFO Carrie Anderson (2x salary+bonus) and Presidents Davis Jr. and McBreen (1.5x).","Qualifying termination within 2 yrs after change in control triggers lump sum, COBRA, outplacement.","Term through Dec 31, 2023; auto-extends upon change in control.","Replaces expiring program; requires release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346554,"accession_number":"0000917520-22-000058","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Integra to acquire SIA for up to $140M; plans $150M share buyback","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Integra buys SIA for $50M at closing plus up to $90M in milestones; deal expected to close by end of 2022.","SIA 2022E revenue ~$5M; gross margin >75%. Acquisition dilutive ~$0.06 in Year 1, accretive in Year 3.","ROIC expected to exceed 10% by Year 5 (2027).","Plans $150M share repurchase starting early 2023 to largely offset Year 1 dilution.","No FDA-approved surgical matrices for IBBR; Integra's SurgiMend PMA under review, DuraSorb IDE ~70% enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346553,"accession_number":"0000917520-22-000051","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences reports Q3 2022 GAAP EPS $0.60, adjusted EPS $0.86; raises FY adjusted EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $385M (-0.4% reported, +3.5% organic); GAAP EPS $0.60 (vs $0.51), adjusted EPS $0.86 (flat YoY).","Codman Specialty Surgical rev $249.8M (-2.6% reported, +1.6% organic); Tissue Technologies rev $135.4M (+3.9% reported, +7.2% organic).","Raised FY2022 adjusted EPS guidance to $3.29-$3.33; reaffirmed rev $1,551M-$1,563M with organic growth 3.7%-4.5%.","Completed TWC divestiture to Gentell for $28.8M ($27.8M cash + $1M contingent consideration).","CereLink recall provision $1.5M, rework $0.8M; return-to-market expected 1H2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1159644000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362947,"accession_number":"0000917520-22-000044","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences enters separation agreement with former COO Glenn Coleman; $1.67M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO position eliminated; separation effective Sept 23, 2022. Severance of $1,668,600 payable in monthly installments over 18 months.","Coleman remains eligible for 2022 annual bonus based on performance goals, paid on normal senior executive schedule.","Previously unvested stock options and restricted stock awards fully vest; options exercisable on original schedule through max expiration.","Performance stock unit awards remain outstanding and eligible to vest upon achievement of performance conditions.","Two-year non-compete and non-solicit covenants apply; non-disparagement clause included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362946,"accession_number":"0001193125-22-231825","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Integra LifeSciences eliminates COO role; Glenn Coleman to exit Oct 3, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO position eliminated effective October 3, 2022.","Glenn Coleman, current COO, will cease employment on that date.","Action is part of succession planning following the 2021 CEO transition.","No replacement named for the eliminated role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362945,"accession_number":"0001193125-22-228064","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Integra LifeSciences voluntarily recalls all CereLink ICP monitors; cuts guidance by $9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary global removal of all CereLink intracranial pressure monitors due to out-of-range readings from electrical interference.","Records $9M returns provision in Q3 2022; Q3 revenue guidance lowered to $374-382M from $383-391M.","Full-year revenue guidance reduced to $1,548-1,566M from $1,557-1,575M; adjusted EPS lowered to $3.12-3.20 from $3.21-3.29.","Low incidence rate at limited sites; investigation ongoing; plans to resume shipments after resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362944,"accession_number":"0000917520-22-000037","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q2 adjusted EPS $0.82 beats prior year; narrows 2022 organic growth guidance to 4.0-5.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $398M, +2% reported (+4.8% organic); GAAP EPS $0.54 vs $0.41; adjusted EPS $0.82 vs $0.79.","Full-year 2022 guidance tightened: organic growth 4.0-5.2%; reported revenue $1,557M-$1,575M; adjusted EPS $3.21-$3.29.","Signed agreement to sell non-core traditional wound care business to Gentell for $28.8M; close expected end of August 2022.","Codman Specialty Surgical revenue $257.9M (+4.3% organic); Tissue Technologies revenue $140.0M (+5.9% organic).","Q3 2022 guidance: reported revenue $383M-$391M, organic growth 2.6-4.8%, adjusted EPS $0.78-$0.82."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":774453000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362943,"accession_number":"0000917520-22-000029","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences appoints Renee Lo as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Renee Lo appointed to board effective July 18, 2022, filling an existing vacancy.","Lo is a general manager at Microsoft leading data and AI business in Asia; previously at Amazon and SAP.","She will receive pro-rated annual board retainer and director equity grant under company policy.","Board determined Lo is independent under Nasdaq and SEC rules; no standing committees assigned yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382616,"accession_number":"0000917520-22-000025","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Integra LifeSciences annual meeting results: all directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected with 72-74M votes each; broker non-votes of 1.9M.","Ratification of PwC as auditor: 75.5M for, 1.2M against, 19k abstain.","Advisory vote on executive compensation approved: 73.7M for, 0.97M against, 72k abstain.","Annual meeting held May 13, 2022; results filed May 17, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382615,"accession_number":"0000917520-22-000021","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Integra LifeSciences Q1 adjusted EPS $0.74 beats prior year; raises FY organic growth guidance to 3.8%-5.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $376.6M (+4.6% reported, +5.6% organic); adjusted EPS $0.74 vs $0.69 Q1 2021; GAAP EPS $0.39 (down from $0.53, prior year included $42.9M divestiture gain).","Codman Specialty Surgical rev $247.3M (org +5.0%); Tissue Technologies $129.3M (org +6.9%).","FY 2022 organic growth guidance raised to 3.8%-5.2% (from 3.5%-5.0%); reported revenue reaffirmed $1.58B-$1.60B; adjusted EPS reaffirmed $3.27-$3.35.","Board authorized new $225M share repurchase program (expires Dec 2024), replacing prior $225M program; completed $125M ASR in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":376638000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400493,"accession_number":"0000917520-22-000007","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q4 revenue $405.5M (+8.3% organic); adj EPS $0.84 flat; guides FY2022 adj EPS $3.27-3.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported revenue $405.5M (+4.3% reported, +8.3% organic); GAAP EPS $0.53 vs $1.09 (prior-year $59.2M tax benefit); adjusted EPS $0.84 flat.","Full-year 2021 revenue $1,542.4M (+12.4% reported, +14.2% organic); GAAP EPS $1.98 vs $1.57; adjusted EPS $3.18 vs $2.45.","Q4 Codman Specialty Surgical organic growth +9.0%; Tissue Technologies organic +6.7%.","FY2022 guidance: revenue $1,580-1,600M (organic +3.5-5%); adjusted EPS $3.27-3.35; Q1 revenue $357-365M, adj EPS $0.67-0.71.","Entered $125M accelerated share repurchase on Jan 12, 2022, expected to complete in H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":1.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":1542448000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-23T23:59:59+00:00|400493"}